Escobar I.G.,Puerta Of Hierro Majadahonda Universitary Hospital |
De Ibarguen B.C.S.,Puerta Of Hierro Majadahonda Universitary Hospital |
De Juan V.C.,Puerta Of Hierro Majadahonda Universitary Hospital |
Alonso C.M.,Puerta Of Hierro Majadahonda Universitary Hospital |
And 3 more authors.
High-dose chemotherapy in lymphomas, and mainly non-Hodgkin's lymphomas, has been advancing since the 1970s. This therapeutic strategy is based on the supposed existence of a dose-response curve for cytotoxic agents. However, the available data are contradictory, so high-dose chemotherapy cannot be guaranteed as consolidation treatment for first-remission follicular lymphoma or diffuse large cell lymphoma. The objective of this paper is to review the current knowledge about high-dose chemotherapy followed by hematopoietic stem cell transplantation in follicular non-Hodgkin's lymphoma. The published studies on follicular lymphoma after first remission, recurrent follicular lymphoma, and transformed follicular lymphoma were assessed together with the data available on diffuse large cell lymphoma. During analysis of the studies, difficulties were encountered in comparing studies due to the heterogeneous nature of the data. High-dose chemotherapy as consolidation treatment after first remission or in recurrent or refractory disease was also analyzed. © 2015 INTM, Italy. Published by Wichtig Publishing. Source